Marcus Blackmore thinks the ASX-listed vitamins group which bears the family name will be among those companies marked down by investors for some time yet, because it is in the basket of stocks with "China exposure''.

Mr Blackmore, who stepped down from the Blackmores board in late October after 47 years as a director, is the largest shareholder with a stake of about 21.5 per cent, worth more than $250 million.